is predicted to decrease the exposure to duloxetine.
▶ SSRIs (fluvoxamine) markedly increase the exposure to
duloxetine. Avoid.rStudy → Also see TABLE 18 p. 1379 → Also
see TABLE 13 p. 1378 → Also see TABLE 4 p. 1375
▶ Teriflunomide is predicted to decrease the exposure to
Dupilumab → see monoclonal antibodies
Durvalumab → see monoclonal antibodies
▶ Antiarrhythmics (dronedarone) are predicted to moderately
increase the exposure to dutasteride.nStudy
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to moderately increase the exposure to
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to dutasteride. Monitor
side effects and adjust dose.oTheoretical
▶ Aprepitant is predicted to moderately increase the exposure to
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
moderately increase the exposure to dutasteride.nStudy
▶ Cobicistat is predicted to increase the exposure to dutasteride.
Monitor side effects and adjust dose.oTheoretical
▶ Crizotinib is predicted to moderately increase the exposure to
▶ HIV-protease inhibitors are predicted to increase the exposure
Monitor side effects and adjust dose.oTheoretical
▶ Imatinib is predicted to moderately increase the exposure to
▶ Macrolides (clarithromycin) are predicted to increase the
dutasteride. Monitor side effects and adjust dose.
▶ Macrolides (erythromycin) are predicted to moderately increase
the exposure to dutasteride.nStudy
▶ Netupitant is predicted to moderately increase the exposure to
▶ Nilotinib is predicted to moderately increase the exposure to
Eculizumab → see monoclonal antibodies
Edoxaban → see TABLE 3 p. 1375 (anticoagulant effects)
▶ Antiarrhythmics (amiodarone) slightly increase the exposure to
▶ Antiarrhythmics (dronedarone) slightly increase the exposure to
edoxaban. Adjust edoxaban dose, p. 126.rStudy
▶ Antiepileptics (carbamazepine) are predicted to decrease the
▶ Antiepileptics (phenytoin) are predicted to decrease the
exposure to edoxaban.oTheoretical
▶ Antifungals, azoles (itraconazole) are predicted to slightly
increase the exposure to edoxaban.rTheoretical
▶ Antifungals, azoles (ketoconazole) slightly increase the exposure
to edoxaban. Adjust edoxaban dose, p. 126.rStudy
▶ Calcium channel blockers (verapamil) are predicted to slightly
increase the exposure to edoxaban.rTheoretical
is predicted to increase the exposure to edoxaban.
▶ Ciclosporin slightly increases the exposure to edoxaban. Adjust
▶ Cobicistat is predicted to increase the exposure to edoxaban.
▶ Eliglustat is predicted to increase the exposure to edoxaban.
▶ HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are
predicted to slightly increase the exposure to
▶ Lapatinib is predicted to slightly increase the exposure to
▶ Macrolides (azithromycin, clarithromycin) are predicted to
slightly increase the exposure to edoxaban.rTheoretical
▶ Macrolides (erythromycin) slightly increase the exposure to
edoxaban. Adjust edoxaban dose, p. 126.rStudy
▶ Mirabegron is predicted to increase the exposure to edoxaban.
▶ Paritaprevir (with ritonavir and ombitasvir) is predicted to
increase the exposure to edoxaban.rStudy
▶ Pibrentasvir (with glecaprevir) is predicted to increase the
▶ Pitolisant is predicted to decrease the exposure to edoxaban.
▶ Ranolazine is predicted to slightly increase the exposure to
is predicted to decrease the exposure to edoxaban.
▶ St John’s Wort is predicted to decrease the exposure to
is predicted to increase the exposure to edoxaban.
▶ Vemurafenib is predicted to slightly increase the exposure to
▶ Voxilaprevir (with sofosbuvir and velpatasvir) is predicted to
Efavirenz → see TABLE 9 p. 1377 (QT-interval prolongation)
▶ Efavirenz is predicted to decrease the exposure to
antiarrhythmics (dronedarone).rTheoretical → Also see
1446 Dorzolamide — Efavirenz BNF 78
▶ Antiepileptics (carbamazepine) slightly decrease the exposure
to efavirenz and efavirenz slightly decreases the exposure to
antiepileptics (carbamazepine).rStudy
▶ Antiepileptics (fosphenytoin, phenytoin) slightly decrease the
exposure to efavirenz and efavirenz affects the concentration
of antiepileptics (fosphenytoin, phenytoin).rTheoretical
▶ Antiepileptics (phenobarbital) are predicted to decrease the
exposure to efavirenz and efavirenz affects the concentration
of antiepileptics (phenobarbital).rTheoretical
▶ Efavirenz is predicted to affect the efficacy of antiepileptics
(primidone) and antiepileptics (primidone) are predicted to
slightly decrease the exposure to efavirenz.rTheoretical
▶ Efavirenz is predicted to decrease the exposure to antifungals,
azoles (isavuconazole). Avoid.rTheoretical
▶ Efavirenz slightly decreases the exposure to antifungals, azoles
. Avoid and for 14 days after stopping efavirenz.
▶ Efavirenz moderately decreases the exposure to antifungals,
▶ Efavirenz slightly decreases the exposure to antifungals, azoles
▶ Efavirenz moderately decreases the exposure to antifungals,
azoles (voriconazole) and antifungals, azoles (voriconazole)
slightly increase the exposure to
Study → Also see TABLE 9 p. 1377
▶ Efavirenz decreases the concentration of antimalarials
(artemether).rStudy → Also see TABLE 9 p. 1377
▶ Efavirenz moderately decreases the exposure to antimalarials
▶ Efavirenz affects the exposure to antimalarials (proguanil).
is predicted to decrease the exposure to aprepitant.
is predicted to decrease the exposure to axitinib.
▶ Efavirenz is predicted to decrease the exposure to bedaquiline.
Avoid.rStudy → Also see TABLE 9 p. 1377
▶ Efavirenz is predicted to decrease the exposure to bosutinib.
Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Efavirenz is predicted to decrease the exposure to brigatinib.
is predicted to decrease the exposure to bupropion.
▶ Efavirenz is predicted to decrease the exposure to
cabozantinib.oTheoretical → Also see TABLE 9 p. 1377
▶ Efavirenz is predicted to decrease the exposure to calcium
channel blockers (amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
▶ Efavirenz is predicted to decrease the exposure to calcium
channel blockers (diltiazem, verapamil).oTheoretical
▶ Efavirenz is predicted to decrease the exposure to cariprazine.
▶ Efavirenz is predicted to decrease the concentration of
caspofungin. Adjust dose.oStudy
▶ Efavirenz decreases the concentration of ciclosporin. Monitor
concentration and adjust dose.oStudy
▶ Efavirenz is predicted to decrease the exposure to cobicistat.
▶ Efavirenz is predicted to decrease the exposure to cobimetinib.
▶ Efavirenz is predicted to decrease the efficacy of combined
hormonal contraceptives. For FSRH guidance, see
Contraceptives, interactions p. 794.rStudy
▶ Efavirenz is predicted to affect the concentration of coumarins.
▶ Efavirenz is predicted to decrease the exposure to crizotinib.
Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Efavirenz increases the risk of increased ALT concentrations
when given with dasabuvir. Avoid.rStudy
is predicted to decrease the exposure to dasatinib.
Study → Also see TABLE 9 p. 1377
▶ Efavirenz is predicted to decrease the efficacy of desogestrel.
Contraceptives, interactions p. 794.
decreases the exposure to dolutegravir. Adjust dose.
▶ Efavirenz is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Efavirenz is predicted to moderately decrease the exposure to
is predicted to decrease the exposure to eliglustat.
▶ Efavirenz is predicted to decrease the concentration of
elvitegravir. Avoid.rTheoretical
is predicted to decrease the effects of ergotamine.
is predicted to decrease the exposure to erlotinib.
▶ Efavirenz is predicted to decrease the efficacy of etonogestrel.
Contraceptives, interactions p. 794.
▶ Efavirenz is predicted to decrease the exposure to etravirine.
▶ Efavirenz is predicted to decrease the concentration of
everolimus. Avoid or adjust dose.rStudy
▶ Efavirenz is predicted to decrease the exposure to
▶ Efavirenz is predicted to decrease the exposure to gefitinib.
▶ Efavirenz is predicted to decrease the exposure to glecaprevir.
▶ Efavirenz is predicted to markedly decrease the exposure to
▶ Efavirenz is predicted to decrease the concentration of
guanfacine. Adjust dose.oTheoretical
▶ Efavirenz decreases the exposure to HIV-protease inhibitors.
Refer to specialist literature.rStudy → Also see TABLE 9
▶ Efavirenz is predicted to decrease the effects of hormone
replacement therapy.oAnecdotal
▶ Efavirenz is predicted to decrease the exposure to idelalisib.
is predicted to decrease the exposure to imatinib.
is predicted to decrease the exposure to ivacaftor.
▶ Efavirenz is predicted to decrease the exposure to lapatinib.
Avoid.rStudy → Also see TABLE 9 p. 1377
▶ Efavirenz is predicted to decrease the concentration of
▶ Efavirenz is predicted to decrease the efficacy of
levonorgestrel. For FSRH guidance, see Contraceptives,
interactions p. 794.rTheoretical
▶ Efavirenz is predicted to decrease the exposure to lurasidone.
Monitor and adjust dose.oTheoretical
▶ Efavirenz decreases the exposure to macrolides
(clarithromycin).oStudy → Also see TABLE 9 p. 1377
▶ Efavirenz decreases the exposure to maraviroc. Refer to
specialist literature.rTheoretical
is predicted to alter the effects of midazolam. Avoid.
is predicted to decrease the exposure to netupitant.
decreases the concentration of efavirenz. Avoid.
▶ Efavirenz is predicted to decrease the exposure to nilotinib.
Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Efavirenz is predicted to decrease the efficacy of
norethisterone. For FSRH guidance, see Contraceptives,
interactions p. 794.rAnecdotal
▶ Efavirenz is predicted to decrease the exposure to olaparib.
▶ Efavirenz is predicted to decrease the exposure to ombitasvir.
▶ Efavirenz decreases the exposure to opioids (methadone).
Monitor and adjust dose.rStudy → Also see TABLE 9 p. 1377
is predicted to decrease the exposure to osimertinib.
Theoretical → Also see TABLE 9 p. 1377
BNF 78 Efavirenz — Efavirenz 1447
is predicted to decrease the exposure to ospemifene.
▶ Efavirenz is predicted to decrease the exposure to paritaprevir
(with ritonavir and ombitasvir). Avoid.rStudy
▶ Efavirenz is predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors.oTheoretical → Also
▶ Efavirenz is predicted to decrease the exposure to pibrentasvir.
▶ Pitolisant is predicted to decrease the exposure to efavirenz.
is predicted to decrease the exposure to quetiapine.
is predicted to decrease the exposure to ribociclib.
Study → Also see TABLE 9 p. 1377
▶ Efavirenz slightly decreases the exposure to rifabutin. Adjust
▶ Rifampicin slightly decreases the exposure to efavirenz. Adjust
▶ Efavirenz is predicted to decrease the exposure to rilpivirine.
▶ Efavirenz is predicted to decrease the exposure to rolapitant.
▶ Efavirenz is predicted to decrease the exposure to ruxolitinib.
Monitor and adjust dose.oTheoretical
▶ Efavirenz is predicted to decrease the concentration of
sirolimus. Monitor and adjust dose.oTheoretical
▶ St John’s Wort is predicted to decrease the concentration of
▶ Efavirenz slightly decreases the exposure to statins
▶ Efavirenz moderately decreases the exposure to statins
▶ Efavirenz is predicted to decrease the concentration of
tacrolimus. Monitor and adjust dose.oTheoretical
▶ Efavirenz is predicted to decrease the exposure to taxanes
▶ Efavirenz is predicted to decrease the concentration of
temsirolimus. Avoid.rTheoretical
is predicted to decrease the exposure to ticagrelor.
is predicted to decrease the exposure to tofacitinib.
▶ Efavirenz decreases the efficacy of ulipristal. For FSRH
Contraceptives, interactions p. 794.r
▶ Efavirenz is predicted to decrease the exposure to velpatasvir.
▶ Efavirenz is predicted to decrease the exposure to venetoclax.
▶ Efavirenz is predicted to decrease the concentration of
voxilaprevir. Avoid.rTheoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Bosentan is predicted to moderately decrease the exposure to
▶ Elbasvir is predicted to increase the concentration of
▶ Efavirenz is predicted to moderately decrease the exposure to
▶ Enzalutamide is predicted to decrease the exposure to elbasvir.
▶ Etravirine is predicted to decrease the exposure to elbasvir.
▶ Mitotane is predicted to decrease the exposure to elbasvir.
▶ Modafinil is predicted to decrease the exposure to elbasvir.
▶ Nevirapine is predicted to moderately decrease the exposure
▶ Rifampicin is predicted to decrease the exposure to elbasvir.
▶ St John’s Wort is predicted to moderately decrease the
exposure to elbasvir. Avoid.rStudy
▶ Elbasvir increases the exposure to statins (atorvastatin). Adjust
atorvastatin dose, p. 202.oStudy
▶ Elbasvir is predicted to increase the exposure to statins
(fluvastatin). Adjust fluvastatin dose, p. 203.qTheoretical
▶ Elbasvir increases the exposure to statins (rosuvastatin). Adjust
rosuvastatin dose, p. 204.oStudy
▶ Elbasvir is predicted to increase the exposure to statins
Use with caution and adjust dose.oTheoretical
Eletriptan → see TABLE 13 p. 1378 (serotonin syndrome)
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
No comments:
Post a Comment
اكتب تعليق حول الموضوع